The tablet Captabine contains Capecitabine and is made by Techno Drugs Ltd. Capecitabine is used to treat some types of cancer.
There are 9 brands of Capecitabine listed in Bangladesh. By unit price, Captabine is among the cheapest of them.
What is Captabine 150 mg Tablet?
Captabine comes as a tablet with 150 mg of Capecitabine, from Techno Drugs Ltd. It contains Capecitabine, a cytotoxic chemotherapy medicine. Capecitabine is a prodrug, which means the body converts it into an active substance that interferes with DNA synthesis and slows tumour growth. The doctor decides whether it is suitable, the dose, and the length of the course.
Uses of Captabine
Capecitabine is used to treat some types of cancer. Do not use it for any other condition, and ask the doctor if you are unsure what it is being used for in your case. Your cancer specialist will explain why it has been prescribed for you. Ask your doctor whether it is right for your condition.
How to use Captabine
Never change the dose or stop on your own. Swallow the tablet with water. Captabine is taken by mouth. Swallow the tablet as your doctor or pharmacist advises. If you miss a dose or vomit after taking it, ask your doctor or pharmacist what to do. Complete the course exactly as prescribed.
Side effects of Captabine
Seek urgent help for severe or worsening symptoms. Some people have serious skin reactions. Common side effects include nausea, vomiting, diarrhoea, stomach pain, mouth sores, loss of appetite, tiredness, rash, dry or itchy skin, fever, infection, chest pain and a hand-and-foot skin reaction. Contact your doctor if you notice anything unusual after taking it. Your doctor will explain which effects need immediate attention and how they should be managed.
Safety and precautions
It can harm an unborn baby, so pregnancy should be avoided during treatment; breastfeeding must stop during treatment and for a time afterwards. It is not for people with severe kidney problems, low blood cell counts, serious reactions to fluoropyrimidine therapy, complete DPD deficiency, or allergy to the medicine. People with heart disease or bleeding problems should be checked first. Tell your doctor about all your other medicines before starting, because Capecitabine can interact with blood thinners, phenytoin, leucovorin and some other drugs.
Frequently asked questions
What is Captabine used for?
Capecitabine is used to treat some types of cancer. Do not use it for any other condition, and ask the doctor if you are unsure what it is being used for in your case.
How do I use Captabine correctly?
Never change the dose or stop on your own. Swallow the tablet with water.
What should I watch for while using Captabine?
Seek urgent help for severe or worsening symptoms. Some people have serious skin reactions.
Capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:
Adjuvant Colon Cancer: Patients with Dukes'C colon cancer.
Metastatic Colorectal Cancer: First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred.
... Read more
Capecitabine is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:
Adjuvant Colon Cancer: Patients with Dukes'C colon cancer.
Metastatic Colorectal Cancer: First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred.
Metastatic Breast Cancer: In combination with docetaxel after failure of prior anthracycline containing therapy.
As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen.
Pharmacology
Capecitabine is a preparation of Capecitabine, an orally-administered chemotherapeutic agent used in the treatment of cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumour, where it inhibits DNA synthesis and slows growth of tumour tissue.
Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumours compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10 methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, therefore a deficiency of this compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis through the production of fraudulent RNA.
Dosage & Administration
Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one-week rest period in 3-week cycles
Adjuvant treatment: Is recommended for a total of 6 months (8 cycles)
In combination with docetaxel: The recommended dose of Capecitabine is 1250 mg/m2 twice daily for 2 weeks followed by a 7-day rest period, combined with docetaxel at 75 mg/m2 as a 1-hour IV infusion every 3 weeks. Capecitabine dosage may need to be individualized to optimize patient management. Capecitabine dosage has to be reduced by 25% in patients with moderate renal impairment.
Example: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily.
The tablets should be taken in morning and evening as prescribed by doctor. The tablets should be taken within 30 minutes after the end of a meal (breakfast and dinner) and swallowed whole with water. Tablets should not be cut or crushed. Capecitabine should only be prescribed by a doctor experienced in the use of anticancer medicines.
Interaction
Anticoagulants: Anticoagulant response (INR or prothrombin time) should be monitored frequently in order to adjust the anticoagulant dose as needed.
Phenytoin: Phenytoin levels should be monitored in patients taking Capecitabine concomitantly with phenytoin. The phenytoin dose may need to be reduced.
Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
CYP2C9 substrates: Care should be exercised when Capecitabine is co-administered with CYP2C9 substrates.
Food: Reduced both the rate and extent of absorption of Capecitabine.
Contraindications
Severe Renal Impairment
Hypersensitivity
leucopenia, neutropenia or thrombocytopenia
Severe reactions to fluoropyrimidine therapy
Complete DPD deficiency
Pregnant or breast-feeding
Side Effects
Abdominal pain, Rash, dry or itchy skin, Tiredness, loss of appetite (anorexia), Diarrhea, Vomiting, Nausea, Stomatitis, Hand-and-foot skin-reaction, Fever, Infection, Chest pain, Steven-Johnson syndrome
Pregnancy & Lactation
Pregnancy category D. Capecitabine can cause fetal harm. Women are advised of the potential risk to the fetus. It is not known whether Capecitabine is excreted in human breast milk.No studies have been conducted to assess the impact of Capecitabine on milk production or its presence in human breast milk. As the potential for harm to the nursing infant is unknown, breast-feeding should be discontinued while receiving treatment with Capecitabine and for 2 weeks after the final dose.
Precautions & Warnings
Coagulopathy: Anticoagulant response should be monitored (e.g. INR) and anticoagulant dose must be adjusted accordingly. Otherwise may result in bleeding, death.
Diarrhea: Capecitabine treatment should be stopped immediately until diarrhea resolves or decreases to grade 1. Standard antidiarrheal treatments recommended. Otherwise may get severe.
Cardiotoxicity: Common in patients with a prior history of coronary artery disease.
Increased Risk of Severe or Fatal Adverse Reactions in Patients with Low or Absent Dihydropyrimidine Dehydrogenase (DPD) Activity: Capecitabine should be withhold or permanently discontinued in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity.
Dehydration and Renal Failure: Capecitabine treatment should be stopped until dehydration is corrected. Potential risk of acute renal failure secondary to dehydration.
Mucocutaneous and Dermatologic Toxicity: Severe mucocutaneous reactions, Steven-Johnson Syndrome. (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Capecitabine should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment. Capecitabine may induce hand-and-foot syndrome. Capecitabine treatment should be interrupted until the hand-and-foot syndrome event resolves or decreases in intensity.
Hyperbilirubinemia: Capecitabine treatment should be interrupted immediately until the hyperbilirubinemia resolves or decreases in intensity.
Hematologic: Patients should not be treated with neutrophil counts <1.5x109/L or thrombocyte counts <100x109/L.
Overdose Effects
The manifestations of acute overdose include nausea, vomiting, diarrhea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary therapeutic and supportive medical interventions aimed at correcting the presenting clinical manifestations and preventing their possible complications.
Storage Conditions
Keep in a dry place and store below 30°C. Protect from light and keep out of the reach of children.
Alternative brands of Capecitabine
Other brands with the same generic name, cheapest first.